-
1
-
-
43749094544
-
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients
-
Brandes AA, Franceschi E, Tosoni A, et al: MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 26:2192-2197, 2008
-
(2008)
J Clin Oncol
, vol.26
, pp. 2192-2197
-
-
Brandes, A.A.1
Franceschi, E.2
Tosoni, A.3
-
2
-
-
42649106522
-
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
-
DOI 10.1016/S1470-2045(08)70125-6, PII S1470204508701256
-
Brandsma D, Stalpers L, Taal W, et al: Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461, 2008 (Pubitemid 351597795)
-
(2008)
The Lancet Oncology
, vol.9
, Issue.5
, pp. 453-461
-
-
Brandsma, D.1
Stalpers, L.2
Taal, W.3
Sminia, P.4
Van Den, B.M.J.5
-
3
-
-
84455185238
-
Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma
-
Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, et al: Pseudoprogression and pseudoresponse: Imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32:1978-1985, 2011
-
(2011)
AJNR Am J Neuroradiol
, vol.32
, pp. 1978-1985
-
-
Hygino Da Cruz Jr., L.C.1
Rodriguez, I.2
Domingues, R.C.3
-
4
-
-
77951625266
-
Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group
-
Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972, 2010
-
(2010)
J Clin Oncol
, vol.28
, pp. 1963-1972
-
-
Wen, P.Y.1
Macdonald, D.R.2
Reardon, D.A.3
-
5
-
-
34548147443
-
Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis
-
DOI 10.2353/jmoldx.2007.060167
-
Mikeska T, Bock C, El-Maarri O, et al: Optimization of quantitative MGMT promoter methylation analysis using pyrosequencing and combined bisulfite restriction analysis. J Mol Diagn 9:368-381, 2007 (Pubitemid 47305073)
-
(2007)
Journal of Molecular Diagnostics
, vol.9
, Issue.3
, pp. 368-381
-
-
Mikeska, T.1
Bock, C.2
EI-Maarri, O.3
Hubner, A.4
Ehrentraut, D.5
Schramm, J.6
Felsberg, J.7
Kahl, P.8
Buttner, R.9
Pietsch, T.10
Waha, A.11
-
6
-
-
33749075532
-
Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03
-
DOI 10.1200/JCO.2006.06.9104
-
Herrlinger U, Rieger J, Koch D, et al: Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. J Clin Oncol 24:4412-4417, 2006 (Pubitemid 46630979)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.27
, pp. 4412-4417
-
-
Herrlinger, U.1
Rieger, J.2
Koch, D.3
Loeser, S.4
Blaschke, B.5
Kortmann, R.-D.6
Steinbach, J.P.7
Hundsberger, T.8
Wick, W.9
Meyermann, R.10
Tan, T.-C.11
Sommer, C.12
Bamberg, M.13
Reifenberger, G.14
Weller, M.15
-
7
-
-
62449086667
-
Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide
-
Glas M, Happold C, Rieger J, et al: Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. J Clin Oncol 27:1257-1261, 2009
-
(2009)
J Clin Oncol
, vol.27
, pp. 1257-1261
-
-
Glas, M.1
Happold, C.2
Rieger, J.3
-
8
-
-
24344436347
-
18F]fluoroethyl)-l- tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas
-
discussion 505-511
-
18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery 57:505-511; discussion 505-511, 2005
-
(2005)
Neurosurgery
, vol.57
, pp. 505-511
-
-
Rachinger, W.1
Goetz, C.2
Pöpperl, G.3
-
9
-
-
69549088562
-
Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: Clinical observations and working recommendations
-
Chaskis C, Neyns B, Michotte A, et al: Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: Clinical observations and working recommendations. Surg Neurol 72:423-428, 2009
-
(2009)
Surg Neurol
, vol.72
, pp. 423-428
-
-
Chaskis, C.1
Neyns, B.2
Michotte, A.3
-
10
-
-
33846955124
-
Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma
-
Chamberlain MC, Glantz MJ, Chalmers L, et al: Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82:81-83, 2007
-
(2007)
J Neurooncol
, vol.82
, pp. 81-83
-
-
Chamberlain, M.C.1
Glantz, M.J.2
Chalmers, L.3
-
11
-
-
78650136376
-
Prolonged response without prolonged chemotherapy: A lesson from PCV chemotherapy in low-grade gliomas
-
Peyre M, Cartalat-Carel S, Meyronet D, et al: Prolonged response without prolonged chemotherapy: A lesson from PCV chemotherapy in low-grade gliomas. Neuro Oncol 12:1078-1082, 2010
-
(2010)
Neuro Oncol
, vol.12
, pp. 1078-1082
-
-
Peyre, M.1
Cartalat-Carel, S.2
Meyronet, D.3
|